3 results match your criteria: "The American University of Beirut Medical Centre[Affiliation]"
J Reprod Infertil
January 2020
Institute for Women's Health, Faculty of Population Health Sciences, University College London, Lebanon, United Kingdom.
Background: The advent of ovarian stimulation within an fertilization (IVF) cycle has resulted in modifying the physiology of stimulated cycles and has helped optimize pregnancy outcomes. In this regard, the importance of progesterone (P4) elevation at time of human chorionic gonadotrophin (hCG) administration within an IVF cycle has been studied over several decades. Our study aimed to evaluate the association of P4 levels at time of hCG trigger with live birth rate (LBR), clinical pregnancy rate (CPR) and miscarriage rate (MR) in fresh IVF or IVF-ICSI cycles.
View Article and Find Full Text PDFBr J Haematol
April 2003
Department of Internal Medicine, The American University of Beirut Medical Centre, Beirut, Lebanon.
Desferrioxamine (DFX) alone (40-50 mg/kg/d s.c. over 8-12 h, five times weekly) was compared with combined DFX twice weekly and deferiprone (75 mg/kg/d) over 12 months in previously poorly chelated thalassaemia patients.
View Article and Find Full Text PDFEur J Haematol
July 2001
The Chronic Care Centre, The American University of Beirut Medical Centre, Beirut, Lebanon.
Introduction: Iron-chelating therapy with deferoxamine in patients with thalassemia major has dramatically improved the prognosis of this disease. However, the limitations of this treatment have stimulated the design of alternative orally active iron chelators.
Objective: To compare the effectiveness and safety of, and compliance with, oral deferiprone (L1), and deferoxamine, in thalassemia major patients.